S pontaneous autoimmune thyroiditis (SAT) 3 in NOD.H2h4 mice is a chronic organ-specific autoimmune disease characterized by infiltration of the thyroid by CD4 ϩ and CD8 ϩ T cells, B cells, and plasma cells and destruction of thyroid follicles by infiltrating inflammatory cells. All NOD.H-2h4 mice develop SAT when they are given 0.05% NaI in their drinking water (1) (2) (3) (4) (5) (6) . All mice produce anti-mouse thyroglobulin (MTg)-specific autoantibodies, and autoantibody levels generally correlate with SAT severity scores (1, 2) . CD4 ϩ T cells are the primary pathogenic effector cells for SAT and are required for both initiation and maintenance of SAT (1) (2) (3) . B cells are required for development of SAT, because B cell-deficient NOD.H-2h4 mice do not develop SAT (7) . Our previous studies suggested that B cells were required for activation of pathogenic CD4 ϩ T cells, possibly functioning as important APCs (7) .
B cells are important for development of most spontaneous autoimmune diseases including SAT, diabetes in NOD mice, systemic lupus erythematosus (SLE) in MRL/Mp-lpr/lpr mice, scleroderma in tight-skin mice, and arthritis in K/BxN mice (7) (8) (9) (10) (11) (12) . B cells produce autoantibodies that contribute to the pathogenesis of autoimmune diseases by multiple mechanisms (13) . However, B cells, including B cells from transgenic mice unable to secrete Ab, can also function in disease pathogenesis, e.g., as important APCs for development of proinflammatory T cell responses (7-9, 14 -18) .
Rituximab is a chimeric mAb that recognizes human CD20, a marker expressed on essentially all mature B cells (13, 19, 20) . Rituximab depletes B cells, and it has been used for treatment of lymphoma, rheumatoid arthritis, and SLE in humans (13, 20 -22) . Although rituximab has been effective for treating several autoimmune diseases and lymphomas, the basis for its efficacy is not entirely clear because the extent of B cell depletion in tissues other than the blood is unknown, and many patients who have benefited from rituximab (anti-CD20) therapy do not have remarkable decreases in autoantibody levels (13, 20 -22) . These results suggest that the therapeutic benefits of rituximab do not result simply from decreased autoantibodies and indicate a need for further mechanistic studies.
Because studies in humans are generally limited to assessment of B cell depletion in peripheral blood, and peripheral blood B cells represent Ͻ2% of all B cells (23) , mechanistic studies in animal models are needed to determine the mechanisms by which anti-CD20 therapy inhibits autoimmune diseases. Until recently, effective reagents for depleting B cells in adult mice were not available. Abs directed against murine CD20 are now available and have shown substantial in vivo depletion of B cells in normal mice (19, 24 -30) , as have mAb to human CD20 (hCD20) in transgenic mice that express hCD20 on B cells (25, 29, 31) . These reagents provide new tools to study in detail the role of B cells in autoimmune diseases.
In this study, mAb directed against murine CD20 were used to determine whether B cell depletion would inhibit development of SAT in NOD.H-2h4 mice. The results indicate that even though most splenic marginal zone (MZ) B cells were resistant to depletion, anti-CD20 markedly inhibited development of SAT and suppressed further development of thyroid lesions and increases in autoantibody production in mice that already had mild SAT when treatment was initiated.
Materials and Methods

Mice
NOD.H-2h4 mice express H-2K
k , I-A k , and D d on the NOD background (1, 32) . They were maintained in the animal facility at the University of Missouri as previously described (2, 6, 7) . Both male and female mice were used, but all mice in an individual experiment were of the same sex. All animal protocols were approved by the University of Missouri Animal Care and Use Committee.
Anti-CD20 and experimental design
IgG1 anti-CD20 mAb 18B12 was generated as previously described (29) . The IgG2a 18B12 mAb was made by combining the V H and V L regions of the IgG1 hybridoma with mouse ␥2A and constant regions, respectively, and expressing the two polypeptide chains in Chinese hamster ovary cells (33) . The IgG1 mouse anti-human 2B8 CD20 mAb with no cross-reactivity to mouse CD20 was used as the isotype control for experiments in mice given anti-CD20 IgG1, and the IgG2a form of the same mAb was used as the isotype control for experiments using anti-CD20 IgG2a. The IgG1 and IgG2a 2B8 Igs were expressed in Chinese hamster ovary cells. All isotype control and anti-CD20 mAbs were purified on protein A columns as previously described (29) . Anti-CD20 and isotype control mAbs (250 -300 g) were initially injected i.v. with subsequent injections given i.p. Results obtained with either isotype control mAb were comparable and did not differ from those in mice given no treatment (data not shown). As previously described (2, 6, 7), 7-to 8-wk-old mice were given 0.05% NaI in the drinking water to induce SAT, and thyroids were removed 7-9 wk later.
Evaluation of SAT severity
After 7-9 wk on NaI water, thyroids were removed, and one thyroid lobe was fixed in formalin, sectioned, and stained with H&E as previously described (2, 6, 7) . The other thyroid lobe was snap frozen in liquid nitrogen, and stored at Ϫ70°C for use in immunohistochemical staining. All slides were scored by two individuals, one of whom had no knowledge of the experimental groups. Thyroid histopathology scores were based on the percentage of thyroid follicles replaced by infiltrating lymphocytes as previously described in detail (2, 6, 7) . Briefly, a score of 0 indicates a normal thyroid, and 0ϩ indicates a few inflammatory cells infiltrating the thyroids and/or mild follicular changes. A 1ϩ severity score is defined as an infiltrate of at least 125 inflammatory cells in one or several foci; a 2ϩ score represents 10 -20 foci of cellular infiltration, each the size of several follicles, with replacement or destruction of up to one-fourth of the gland; a 3ϩ score indicates that one-fourth to one-half of the thyroid follicles are destroyed or replaced by infiltrating inflammatory cells; and 4ϩ indicates that greater than one-half of the gland is replaced or destroyed.
Autoantibody determination
MTg-specific autoantibodies were determined by ELISA using serum from individual mice as previously described (2, 7).
Immmunohistochemical staining
Frozen thyroids were sectioned and stained as previously described (6) using anti-CD4 (GK1.5; American Type Culture Collection) and anti-B220 (Caltag Laboratories). Biotinylated goat anti-rat-IgG (CaltagLaboratories) was used as secondary Ab, and 0.3% hydrogen peroxide was used to block endogenous peroxidase. Sections were incubated with Vectastain Elite avidin-biotin complex (Vector Laboratories), and peroxidase activity was visualized using Nova Red substrate (Vector). Negative controls used IgG isotype controls as the primary Ab, with the remaining steps performed as described previously. These controls were always negative.
Flow cytometry
Peripheral blood, spleen, or cervical lymph node (CLN) cells from experimental mice were analyzed for expression of CD4, CD19, B220, CD21, and CD23 by flow cytometry (FACScan and FACSCalibur) as described previously (7). Abs were obtained from eBioscience or BD Pharmingen.
Statistical analysis
A two-tailed Student's t test was used to determine the significance of differences in SAT severity between different groups. The p values are given in the footnotes to the tables, and p values of Ͻ0.05 were considered significant.
Results
Differential susceptibility of B cells in spleen, lymph node, and blood to depletion by anti-CD20
To determine whether anti-CD20 could effectively deplete B cells in NOD.H-2h4 mice, 7-to 8-wk-old mice were given a single injection of 250 g of anti-CD20 mAb 18B12 (mouse IgG1 or mouse IgG2a) or the corresponding isotype control i.v. The percentages of total B cells in peripheral blood, CLN, and spleens were determined 4 or 7, 14, and 21 days later. After 4 or 7 days, 80 -90% of B cells in peripheral blood ( Fig. 1 and Table I ) and CLNs (data not shown) were depleted using either of the anti-CD20 mAbs. However, only ϳ50% of splenic CD19 ϩ B cells were depleted after 7-14 days in most mice given a single injection of anti-CD20 IgG1 mAb, whereas depletion of splenic B cells was usually greater (60 -70%) after 7 or 14 days in most mice given anti-CD20 IgG2a mAb ( Fig. 1 and Table I ). Increasing the amount of anti-CD20 to 500 -1000 g did not result in increased depletion of splenic B cells, and a lower dose of 100 g was less effective (data not shown). B cell depletion in blood, CLNs, and spleen was usually comparable 1 and 2 wk after a single injection of 250 -300 g of either anti-CD20 mAb (Table I) . After 3 wk, B cells remained at very low levels in blood, but splenic B cell numbers increased to 60 -70% of those in mice given either of the isotype control mAbs (Table I and data not shown). In general, B cells in blood began to increase ϳ4 wk after a single injection of 250 -300 g of anti-CD20 but did not return to levels seen in mice given isotype control or no mAb for 7-8 wk (data not shown). Although the extent of splenic B cell depletion was variable in the many individual mice examined in these experiments, the overall conclusion is that both IgG1 and IgG2a anti-CD20 mAbs effectively deplete B cells in blood and CLNs of NOD.H-2h4 mice, but depletion of splenic B cells is incomplete.
MZ B cells in NOD.H-2h4 mice are resistant to depletion by anti-CD20
Because some splenic B cells were resistant to depletion by anti-CD20, it was of interest to determine whether a particular subpopulation of splenic B cells might be resistant to depletion by anti-CD20. To address this issue, three-color flow cytometry was used to determine the phenotypes of residual splenic B cells in mice given anti-CD20 7 days previously (Fig. 2) high represent transitional 2 (T2) MZ precursor B cells (34 -36) . Most FO and T2 B cells were depleted in spleens of anti-CD20 treated NOD.H-2h4 mice. Most residual splenic B cells in mice given anti-CD20 were MZ B cells, although some FO and T2 B cells were also resistant to depletion by both isotypes of anti-CD20 (Fig. 2) . As mentioned above, both anti-CD20 mAbs effectively depleted 80 -90% of B cells in CLNs and blood, and this is consistent with the fact that MZ B cells are noncirculating; i.e., B cells in blood and LN are primarily FO B cells (Ref. 34 and data not shown).
Effect of anti-CD20 on development of SAT
To determine whether anti-CD20 could inhibit development of SAT, 7-wk-old NOD.H-2h4 mice were given 300 g of IgG1 anti-CD20 or the IgG1 isotype control i.v. One week later, they were given NaI in their water to initiate development of SAT (Table II). Anti-CD20 and isotype control injections were repeated 3 and 6 wk later, and thyroids were removed 2 wk after the last injection. During the experiment, analysis of peripheral blood by flow cytometry showed that Ͼ80% of B cells in blood were depleted at all times tested (data not shown). SAT was only marginally inhibited in mice given IgG1 anti-CD20, and anti-MTg autoantibody responses were slightly, but not significantly, lower than in isotype controls (Table II) . Similar results were observed in two other experiments (not shown). At the time thyroids were removed, ϳ50% of splenic B cells were depleted in the anti-CD20-treated mice compared with isotype controls (Table II) .
Previous results of others suggest that depletion of B cells by anti-CD20 involves Fc␥R-dependent pathways, and IgG2a mAbs are the most effective isotype for depletion of B cells in vivo (37, 38) . The results in Fig. 1 and Table I indicate that the 18B12 IgG2a mAb was more effective than the IgG1 mAb for depletion of splenic B cells. To determine whether the IgG2a 18B12 mAb would be more effective for inhibiting development of SAT, 7-wkold mice were given 300 g of anti-CD20 IgG2a or IgG2a isotype control i.v. After 1 wk, they were given NaI in their drinking water, and injections of anti-CD20 IgG2a or isotype control were repeated 3 and 6 wk later. Thyroids were removed 2 wk after the last injection (Table III) . Peripheral blood B cells were monitored several times during the experiment, and CD19 ϩ B cells in blood were almost completely depleted (80 -90%) at all times (data not shown). In multiple experiments, three of which are shown in Table III, mice given IgG2a anti-CD20 had significantly reduced SAT severity scores compared with isotype controls. Anti-MTg autoantibody responses were also significantly lower in anti-CD20-treated mice in the three experiments in Table III . At the time thyroids were removed, depletion of splenic B cells in individual mice was variable, ranging from a low of 25-30% to as high as 80 -90% in some mice. Interestingly, there was no correlation between the SAT severity scores and percentages of splenic B cells in individual mice at the end of the experiments (data not shown), suggesting that complete depletion of splenic B cells was not necessary for effective disease suppression. Consistent with the results in Fig. 2 , most of the residual splenic B cells in anti-CD20-treated mice in the experiments in Table III were MZ B cells (data not shown). Thus, depletion of most circulating (predominantly FO) B cells by IgG2a anti-CD20 reduces development of SAT, suggesting that mature CD20 ϩ B cells are important for development of SAT. The results also suggest that effective suppression of SAT and anti-MTg autoantibody responses is possible even though some B cell subsets, especially MZ B cells, are relatively resistant to depletion.
It is not clear why the IgG1 anti-CD20 was less effective than the IgG2a mAb for inhibiting SAT development, because neither mAb effectively depleted MZ B cells, and differences in the extent of depletion of FO and T2 B cells by the two mAbs were fairly minimal (Fig. 2) . IgG1 anti-CD20 was also shown by others to be less effective than IgG2a for depletion of B cells in NOD mice (38) .
Effect of anti-CD20 on ongoing SAT
Although anti-CD20 is effective for treating established autoimmune diseases in humans, it had little effect when given after disease onset in several murine models (26 -28) . Therefore, it was important to determine whether SAT would be inhibited by the 18B12 anti-CD20 IgG2a mAb if injections began after mice had begun to develop thyroid lesions and anti-MTg autoantibodies. To address this question, groups of mice were given IgG2a anti-CD20 or isotype control beginning 5 (Table IV, a Seven-week-old NOD.H-2h4 mice were given 300 g of IgG1 anti-CD20 or the IgG1 isotype control i.v. and the injections were repeated i.p. 3 and 6 wk later. All mice were given 0.05% NaI in their drinking water at 8 wk of age. Thyroids were removed 2 wk after the last anti-CD20 injection.
b Numbers of mice with various degrees of severity of SAT 8 wk after NaI water ( p Ͼ 0.05 (line 1 vs line 2)).
c Anti-MTg IgG (1/100 serum dilution) expressed as OD 410 Ϯ SEM ( p ϭ 0.06; line 1 vs line 2).
d Percentages of splenic CD19 ϩ B cells at termination of the experiments (mean Ϯ SEM of all mice in the group) ( p Ͻ 0.01; line 1 vs line 2). Expt. 1 (lines 1-3 ), mice were given NaI water at 8 wk of age. Five weeks later, thyroids were removed from one group of mice (line 1), and the remaining mice were given the IgG2a isotype control (line 2) or 300 g anti-CD20 IgG2a i. v. (line 3). Injections were repeated i.p. 3 and 6 wk later, and thyroids were removed 2 wk after the last injection (11 wk after beginning NaI water). In Expt. 2 (lines 4 -6), mice were given NaI water at 8 wk of age. Thyroids were removed from one group of mice 8 wk later (line 4) and the remaining mice were given anti-CD20 IgG2a or the IgG2a isotype control as in Expt. 1. Thyroids were removed 2 wk after the last injection (14 wk after beginning NaI water).
Table III. IgG2a anti-CD20 inhibits development of SAT
b Numbers of mice with various degrees of severity of SAT before and after administration of anti-CD20 or IgG2a isotype control . p Ͻ 0.05 (line 2 vs line 3 and line 5 vs line 6). lines 4 -6) weeks after NaI water. Thyroids and serum were obtained from groups of five mice in each experiment to confirm the extent of inflammation and levels of autoantibodies present when anti-CD20 injections began (Table IV) . Thyroid lesions and antiMTg autoantibodies were present in most mice 5 (Table IV, line 1) or 8 (Table IV, line 4) weeks after NaI water when anti-CD20 injections began. Other groups of mice in the same experiments were given three injections of IgG2a anti-CD20 or the IgG2a isotype control at 3-wk intervals, and experiments were terminated 2 wk after the last injection. SAT severity was significantly reduced in both experiments in mice given IgG2a anti-CD20 after inflammation had begun to develop (Table IV, line 2 vs line 3 and line  5 vs line 6 ). When B cell depletion was initiated in mice that had begun to develop SAT and produce autoantibody, circulating antiMTg autoantibodies in anti-CD20-treated mice were only slightly higher than those present before anti-CD20 treatment (Table IV , line 1 vs line 3 and line 4 vs line 6), whereas anti-MTg autoantibodies in mice given isotype control mAb continued to increase (Table IV) . When thyroids were removed for evaluation of thyroid histopathology, 40 -60% of splenic B cells were depleted in anti-CD20-treated mice (Table IV) , and as mentioned above, there was no correlation between the percentage of splenic CD19
ϩ B cells present at the time of thyroid removal with the SAT severity scores. This suggests that depletion of circulating B cells, which was always essentially complete throughout the experiment, was the most important predictor of disease suppression in anti-CD20-treated mice. Depletion of B cells in blood and spleens of mice given anti-CD20 IgG2a after disease had begun to develop was comparable with that shown for naive mice in Table I (data not shown).
Reduction of both T and B cells in thyroids after anti-CD20 treatment
IgG2a anti-CD20 markedly inhibited SAT development, and inflammatory cell infiltration of the thyroid was therefore reduced (Fig. 3) . When anti-CD20 injections were initiated after SAT had begun to develop, T and B cells had already migrated to the thyroid. Infiltration of both B and T cells was reduced in mice given anti-CD20, and clustering of T and B lymphocytes which was evident in isotype controls was minimal (Fig. 3) . These results suggest that B cells may be required for maintenance of inflammation in SAT, and when circulating B cells (including those that migrate to the thyroid) are depleted, effector CD4 ϩ T cells are not retained in the inflammatory site.
Discussion
The results of this study indicate that development of SAT and anti-MTg autoantibody responses were reduced in NOD.H-2h4 Table IV . A-D, Inflammatory cells present in thyroids before anti-CD20 injections began (2ϩ severity). E-H, Inflammatory cells in thyroids of mice given isotype control (2ϩ severity). I-L and M-P, Inflammatory cells in thyroids of mice given IgG2a anti-CD20 as indicated in Table IV . I-L, Thyroid with a 0ϩ severity score; M-P, thyroid with a 1ϩ severity score. A, C, E, G, I, K, M, and O, ϫ100; B, D, F, H, J, L, N, and P, ϫ400 views of the same thyroids.
mice given anti-CD20 IgG2a mAb. SAT severity scores were also reduced in mice given anti-CD20 IgG2a if treatment was initiated after disease had begun to develop (Table IV) . Because plasma cells reportedly do not express CD20 (21, 39) , anti-MTg autoantibody responses in anti-CD20-treated mice were comparable with those present when treatment began, whereas Ab responses continued to increase in isotype controls. In these experiments (Table  IV) , SAT severity scores were relatively mild (2ϩ in most mice) when treatment was initiated. It is not known whether anti-CD20 would be effective in mice with more severe SAT.
In other studies, anti-CD20 given before disease onset prevented development of collagen induced arthritis, fibrosis in tight-skin mice, Sjögren's syndrome, and diabetes in mice but had little effect in mice with ongoing disease (26 -28, 38) . However, the same anti-CD20 IgG2a Ab used here effectively inhibited proteoglycaninduced arthritis in mice that had already begun to develop arthritis and autoantibodies (30) . The IgG1 18B12 mAb inhibited ongoing SLE in MRL/lpr mice (29) , and anti-hCD20 effectively suppressed some clinical signs of SLE and diabetes in transgenic MRL/lpr (29) or NOD (31) mice expressing hCD20 on B cells. The reason(s) for the differences in effectiveness of anti-CD20 in suppressing ongoing disease in different animal models are not known but may be due to differences in requirements for B cells in disease initiation vs their role in maintaining disease in different models. Previous studies have established an important role for B cells in initiation of many autoimmune diseases, where they presumably function as important APCs (7-9, 14 -18) to promote activation of pathogenic CD4
ϩ T cells (29 -31, 40) . Experiments using B cell-deficient mice and mice depleted of B cells beginning at birth indicate that B cells are required for development of many autoimmune diseases including SAT (7-12, 14 -18) . In those studies, B cell depletion was essentially complete, and in B cell-deficient mice, B cells are completely absent throughout development; this may result in abnormalities that extend beyond simple B cell depletion (40) . The results presented here indicate that anti-CD20 given to adult NOD.H-2h4 mice reduced development of SAT and autoantibody responses even though most splenic MZ B cells were resistant to depletion. These results are consistent with those of others (29, 31, 38) , indicating that B cells in autoimmunity-prone mouse strains are relatively resistant to depletion by anti-CD20 compared with those in nonautoimmunity-prone strains. B cells in autoimmunity-prone mice could be more resistant to depletion because autoreactive B cells are presumably activated before development of autoimmune diseases, and activated B cells could be more resistant to depletion by anti-CD20 (29) . Alternatively, the relatively greater resistance of B cells from autoimmunity-prone mice, particularly those of NOD mice, to depletion by anti-CD20 could be due to deficient Fc␥RI binding of IgG2a anti-CD20 and/or decreased numbers of splenic monocytes in NOD mice compared with C57BL/6 mice (38). Because NOD.H-2h4 mice differ from NOD mice only at the MHC locus (2, 32) , the defects in Fc␥R effector functions in NOD mice (38, 41, 42) are presumably also present in NOD.H-2h4 mice. The relative resistance of some splenic B cells to depletion by anti-CD20 in our studies might also be explained by the fact that some NOD.H-2h4 mice given anti-CD20 IgG2a generated an immune response against the variable domain of the IgG2a anti-CD20 Ab, because circulating anti-idiotypic Abs were detected in some mice (data not shown). This explanation, however, is unlikely to account for the relative resistance to depletion of splenic B cells in most mice because only a very small percentage of sera had detectable anti-idiotypic Abs, these Abs were never detected in mice given IgG1 anti-CD20, and MZ B cells were resistant to depletion in all mice.
Previous studies by others indicated that circulating mature B cells were almost completely depleted by anti-hCD20 in transgenic mice expressing hCD20 on B cells after injection of anti-hCD20, but most MZ B cells were resistant to depletion (25) . The results presented here indicate that the CD21 high CD23 low splenic MZ B cell compartment in NOD.H-2h4 mice was almost completely resistant to depletion by anti-CD20, whereas most splenic FO and transitional T2 B cells were depleted (Fig. 2) . The resistance of MZ B cells to depletion by anti-CD20 is not due to lack of CD20 expression by MZ B cells or to lack of binding of the mAb to MZ B cells (25, 38) . In some models, MZ, T2, and FO B cells were depleted to a similar extent by anti-CD20 (26 -30, 38) . To our knowledge, our studies are the first to show that splenic MZ B cells are relatively resistant to depletion by anti-CD20 compared with other splenic B cell subsets. This suggests that B cell subsets in different mouse strains might differ in their susceptibility to depletion by anti-CD20. However, other factors are apparently also important because a different anti-CD20 mAb effectively depleted MZ B cells in NOD mice (38) , which are closely related to the NOD.H-2h4 mice used here. Importantly, the splenic B cells (primarily MZ B cells) that were not depleted in NOD.H-2h4 mice given IgG2a anti-CD20 were apparently insufficient and/or were not required to initiate development of SAT in NOD.H-2h4 mice.
The finding that anti-CD20 was relatively effective when anti-CD20 was given to mice that had already begun to develop SAT (Table IV) suggests that B cells play a role both in initiation of SAT and in maintaining chronic inflammation in the thyroid. Several studies support an active role for B cells in the diversification of autoreactive T cell responses, and T cell-B cell interactions constitute a positive feedback loop that enables diversification and continuous amplification of autoimmune responses (43) (44) (45) (46) (47) . B cells also contribute to inflammation by functioning as APCs for activation of autoreactive T cells (8, 14 -18) and by producing autoantibodies and proinflammatory cytokines (28, (47) (48) (49) (50) . In the current study, infiltration of both T and B cells in thyroids was reduced when anti-CD20 was given to mice that had already developed SAT (Fig. 3) . This is consistent with a recent report indicating that rituximab depleted intrathyroidal B cells in a patient with Graves' disease (51) . B cells that migrate to the thyroid may promote infiltration and proliferation of autoreactive CD4 ϩ T cells to form tertiary lymphoid organs found in many autoimmune disease target tissues, including thyroids of NOD.H-2h4 mice with SAT (6, 48 -50, 52, 53) . B cells can be important for the formation and maintenance of these structures (49, 50) , and B cell depletion could lead to dissolution of these organized lymphoid infiltrates as suggested by our finding that thyroid-infiltrating cells in anti-CD20-treated mice tended to be scattered, whereas those in mice given isotype control form clusters (Fig. 3) , shown previously to be comprised of CD4 ϩ T cells and B220 ϩ B cells (6) . Because infiltration of both CD4 ϩ T cells and B cells decline after treatment with anti-CD20, T cells apparently die or are not retained in the thyroid after B cells are depleted.
In addition to their role in promoting autoimmune diseases, B cells can function as regulatory cells to suppress progression and/or promote recovery in several murine models of chronic inflammation (54) , including inflammatory bowel diseases (54 -56) , rheumatoid arthritis (36, (57) (58) (59) , and experimental autoimmune encephalomyelitis (60) . In some reports, B cells were shown to negatively regulate inflammatory responses by producing IL-10 (36, 54, (57) (58) (59) (60) . In some of these studies, IL-10-producing regulatory B cells were MZ-like B cells, characterized by expression of high levels of CD1d and responsiveness to LPS (57), whereas in others, regulatory B cells were reported to be mesenteric (56) or transitional type 2 cells (36, 57, 59 ) that include precursors of MZ B cells (34 -36) . FO, MZ, and transitional B cells could have different roles in development of some autoimmune diseases, with FO B cells functioning to promote disease and MZ or transitional B cells functioning to inhibit disease. Consistent with this notion, constitutive expression of B7-1 on B cells of NOD mice resulted in marked reduction of splenic FO B cells, whereas MZ B cells were largely unaffected. The transgenic mice had reduced insulitis and did not develop diabetes (61) , suggesting that MZ B cells were not sufficient to initiate development of diabetes and could be functioning as regulatory cells. In the current study, anti-CD20 effectively suppressed SAT development even though most MZ B cells were resistant to depletion. It is possible that the splenic MZ B cells in anti-CD20-treated NOD.H-2h4 mice could contribute to suppression of SAT, e.g., through production of IL-10. We are currently generating IL-10 Ϫ/Ϫ NOD.H-2h4 mice to address a possible role of IL-10 and MZ B cells in suppression of SAT in anti-CD20-treated mice.
Although multiple factors in addition to B cells contribute to autoimmune disease pathogenesis, understanding the contributions of different subsets of B cells to autoimmune diseases is important. More detailed analyses of the mechanisms involved in suppression of autoimmune diseases after B cell depletion in animal models will lead to a better understanding of the potential applications of B cell-depleting therapies for autoimmune and inflammatory diseases in humans. In addition to its effectiveness in suppressing autoimmune diseases such as SLE and rheumatoid arthritis, anti-CD20 has been suggested to be a potential effective treatment for Graves'-associated ophthalmopathy and hyperthyroidism in humans (51, (62) (63) (64) , although it had minimal effects on autoantibody responses in most patients (63, 64) .
